Merck (MRK -1.1%) has filed patent infringement litigation in New Jersey against Teva Pharmaceutical Industries (TEVA -1.6%) in a move to block the market entry of the latter’s generic version of antibiotic Dificid (fidaxomicin).
Merck claims that Teva’s candidate infringes on five Dificid patents, one expiring in January 2024 and four in January 2028. It sued Teva in 2015 over the same patents (case still pending).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.